Non-Infectious Macular Edema Treatment Market is Projected to Expand at 6.9% CAGR to US$ 29.6 Billion by 2034 | Fact.MR Report
03 févr. 2025 07h30 HE
|
FACT.MR
Rockville, MD, Feb. 03, 2025 (GLOBE NEWSWIRE) -- The global non-infectious macular edema treatment market is anticipated to secure a valuation of US$ 15,121.9 million in 2024. The global market is...
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds
29 janv. 2025 17h30 HE
|
Silexion Therapeutics Corp
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
28 janv. 2025 08h29 HE
|
Silexion Therapeutics Corp
Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for...
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering
15 janv. 2025 20h00 HE
|
Silexion Therapeutics Corp
Cayman Islands, January 15, 2025 -- Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies
15 janv. 2025 16h01 HE
|
Silexion Therapeutics Corp
Cayman Islands, January 15, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium
13 janv. 2025 07h50 HE
|
Silexion Therapeutics Corp
Cayman Islands, January 13, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
17 déc. 2024 06h30 HE
|
Silexion Therapeutics Corp
Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors
10 déc. 2024 08h30 HE
|
Silexion Therapeutics Corp
Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven...
Silexion Therapeutics Announces 1-for-9 Reverse Share Split
22 nov. 2024 16h30 HE
|
Silexion Therapeutics Corp
GRAND CAYMAN, Cayman Islands, November 22, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for...
Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
20 nov. 2024 08h30 HE
|
Silexion Therapeutics Corp
GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers,...